Research Papers:

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

Gemma Bruera, Silvia Massacese, Stefania Candria, Antonio Galvano, Rosa Manetta, Aldo Victor Giordano, Sergio Carducci, Alessandra Di Sibio, Eugenio Ciacco, Antonio Russo _, Enrico Ricevuto and on behalf of Oncology Network ASL1 Abruz, Italy

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:31861-31876. https://doi.org/10.18632/oncotarget.25870

Metrics: PDF 1062 views  |   HTML 1498 views  |   ?  


Gemma Bruera1,2, Silvia Massacese3, Stefania Candria1, Antonio Galvano4, Rosa Manetta5, Aldo Victor Giordano5, Sergio Carducci5, Alessandra Di Sibio5, Eugenio Ciacco3, Antonio Russo4, Enrico Ricevuto1,2 and on behalf of Oncology Network ASL1 Abruzzo, Italy

1Oncology Territorial Care Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, University of L’Aquila, L’Aquila, Italy

2Department of Biotechnological and Applied Clinical Sciences, University of L’Aquila, L’Aquila, Italy

3Pharmacy Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy

4Medical Oncology Unit, Department of Surgical, Oncological and Stomatological Sciences, University of Palermo, Palermo, Italy

5Radiology Unit, S. Salvatore Hospital, Oncology Network ASL1 Abruzzo, L’Aquila, Italy

Correspondence to:

Antonio Russo, email: [email protected]

Keywords: FIr/FOx; first-line; metastatic pancreatic ductal adenocarcinoma; phase II study; triplet chemotherapy

Received: March 29, 2018    Accepted: July 18, 2018    Published: August 07, 2018


Background: Gemcitabine/nab-paclitaxel and FOLFIRINOX demonstrated significantly increased survival compared with gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): objective response rate (ORR) 23 and 31.6%, progression-free survival (PFS) 5.5 and 6.4 months, overall survival (OS) 8.7 and 11.1 months. Present phase II study evaluated recommended first-line triplet FIr/FOx schedule.

Methods: Simon two-step design: p010%, p130%, power 80%, α5%, β20%. Projected ORR: I step, 1/10; II 5/29. Schedule: 12h-timed-flat-infusion/5-fluorouracil 750-800-900 mg/m2 d1-2,8-9,15-16,22-23; irinotecan 120-140-160 mg/m2 d1,15; oxaliplatin 70-80 mg/m2 d8,22; every 4 weeks, according to clinical parameters (age, comorbidities, performance status (PS), liver function). Activity and efficacy were evaluated, and compared using log-rank; limiting toxicity syndromes (LTS), using chi-square.

Results: Twenty-nine consecutive patients were enrolled, according to primary/intermediate/secondary Cumulative Illness Rating Scale (CIRS). Median age 62; elderly 13 (44.7%); PS2 3 (10.4%), secondary CIRS 5 (17.2%). Primary endpoint was met: ORR 53% (7/13 patients) as-treated, 50% intent-to-treat. Cumulative G3-4 toxicities: diarrhea 17%, asthenia 14%, hypertransaminasemy 7%, mucositis 7%, vomiting 3%, anemia 3%, thrombocytopenia 3%. LTS were 27.5% overall, 38.4% in elderly. At 3 months median follow-up, PFS 4 months, OS 11 months. PS2 patients showed significantly worse OS (P 0.022).

Conclusion: Intensive first-line triplet FIr/FOx is tolerable at modulated doses, and confirms high activity/efficacy in metastatic PDAC. Patients’ careful selection, and exclusion of PS2, can maintain safety profile and efficient dose intensity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25870